HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Associations of Clinical and Dosimetric Parameters with Urinary Toxicities after Prostate Brachytherapy: A Long-Term Single-Institution Experience.

Abstract
To examine the association of clinical, treatment, and dose parameters with late urinary toxicity after low-dose-rate brachytherapy (LDR-BT) for prostate cancer, we retrospectively studied patients with prostate cancer who underwent LDR-BT from January 2007 through December 2016. Urinary toxicity was assessed using the International Prostate Symptom Score (IPSS) and Overactive Bladder (OAB) Symptom Score (OABSS). Severe and moderate lower urinary tract symptoms (LUTS) were defined as IPSS ≥ 20 and ≥ 8, respectively; OAB was defined as a nocturnal frequency of ≥ 2 and a total OABSS of ≥ 3. In total, 203 patients (median age: 66 years) were included, with a mean follow-up of 8.4 years after treatment. The IPSS and OABSS worsened after 3 months of treatment; these scores improved to pretreatment levels after 18-36 months in most patients. Patients with a higher baseline IPSS and OABSS had a higher frequency of moderate and severe LUTS and OAB at 24 and 60 months, respectively. LUTS and OAB at 24 and 60 months were not correlated with the dosimetric factors of LDR-BT. Although the rate of long-term urinary toxicities assessed using IPSS and OABSS was low, the baseline scores were related to long-term function. Refining patient selection may further reduce long-term urinary toxicity.
AuthorsMasaya Ito, Chiyoko Makita, Takayuki Mori, Hirota Takano, Tomoyasu Kumano, Masayuki Matsuo, Koji Iinuma, Makoto Kawase, Keita Nakane, Masahiro Nakano, Takuya Koie
JournalCurrent oncology (Toronto, Ont.) (Curr Oncol) Vol. 30 Issue 6 Pg. 5680-5689 (06 09 2023) ISSN: 1718-7729 [Electronic] Switzerland
PMID37366909 (Publication Type: Journal Article)
Topics
  • Male
  • Humans
  • Aged
  • Prostate
  • Retrospective Studies
  • Brachytherapy (adverse effects)
  • Urinary Bladder, Overactive (diagnosis, etiology)
  • Lower Urinary Tract Symptoms (etiology, diagnosis)
  • Prostatic Neoplasms (radiotherapy, etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: